Skip To Main Content

EMICIZUMAB DATA

Patient Management Topics

Medical Information Letters

The Genentech resources below are patient-friendly summaries of data related to emicizumab and select management topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.

Breakthrough Bleeds

HEMLIBRA and Treating Breakthrough Bleeds in Hemophilia A Without Inhibitors

Laboratory Tests 

HEMLIBRA Effect
on Laboratory Monitoring Tests for Clotting
 

Surgeries and Procedures

HEMLIBRA and
Surgeries and Procedures

 


Publications And Scientific Presentations

Select publications and scientific data presentations with the strongest and most relevant data are provided below.

 

Breakthrough Bleeds

Factor VIII Use in the Treatment of Breakthrough Bleeds in Persons With Hemophilia A Without Inhibitors on Emicizumab Prophylaxis: The Phase III HAVEN 3 Study Experience

Callaghan M, Trzaskoma B, Ko R, et al. Presented at the Virtual HFA Scientific Meeting; August 24-29, 2020.

Laboratory Tests

Effects and Interferences of Emicizumab, a Humanized Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Adamkewicz JI, Chen DC, Paz-Priel Il. Thromb Haemost. 2019;119:1084–1093.

 

Surgeries and Procedures

Surgical Experience From Four Phase III Studies (HAVEN 1-4) of Emicizumab in Persons With Haemophilia A (PwHA) With or Without FVIII Inhibitors

Santagostino E, Oldenburg J, Chang T, et al. Presented at ISTH; July 6–10, 2019; Melbourne, Australia.

Surgical Experience From the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons With Hemophilia A (PwHA) With FVIII Inhibitors: Data From the Second Interim Analysis

Castaman G, Santagostino E, Kremer Hovinga J, et al. Presented at the Virtual ISTH Scientific Meeting; July 12-14, 2020.